Overview
GE HealthCare Technologies Inc., based in the United States, operates within the healthcare sector, primarily focusing on medical technology and digital solutions. As a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, GE Healthcare provides healthcare professionals and their patients with a comprehensive range of diagnostic, therapeutic, and monitoring products. The company is pivotal in enhancing precision health by delivering integrated solutions, including imaging, ultrasound, and informatics, alongside enterprise software and services used across diagnostics and monitoring. Key projects often involve collaborations with hospitals and research institutions aimed at advancing technologies such as AI-enhanced imaging systems and improving patient outcomes through more accurate and efficient diagnostic capabilities. GE HealthCare Technologies continues to be at the forefront of innovation in the healthcare industry, driving both technological advancement and accessible care.
AI+ Ask Fintel’s AI assistant about GE HealthCare Technologies Inc..
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of GE HealthCare Technologies Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 0.00 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | 2025-07-25 |
| Borrow Rate | |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 5.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for GE HealthCare Technologies Inc. is MX$1,665.71. The forecasts range from a low of MX$1,383.82 to a high of MX$2,088.95. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for GE HealthCare Technologies Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-05-30 | Goldman Sachs | Neutral | Initiate | |
| 2024-05-01 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-05-01 | Mizuho | Buy | Buy | Maintains |
| 2024-04-11 | Mizuho | Buy | Buy | Maintains |
| 2024-04-04 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-04-03 | Citigroup | Buy | Buy | Maintains |
| 2024-04-01 | Argus Research | Buy | Buy | Maintains |
| 2024-02-15 | HSBC | Buy | Initiate | |
| 2024-02-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-02-12 | UBS | Sell | Neutral | Upgrade |
| 2024-02-07 | Mizuho | Buy | Buy | Maintains |
| 2023-12-04 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-11-30 | Jefferies | Hold | Initiate | |
| 2023-11-27 | UBS | Neutral | Sell | Downgrade |
| 2023-09-19 | Citigroup | Buy | Initiate | |
| 2023-08-16 | Wells Fargo | Overweight | Initiate | |
| 2023-07-31 | B of A Securities | Neutral | Initiate | |
| 2023-07-26 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-06-28 | Morgan Stanley | Equal-Weight | Initiate | |
| 2023-06-27 | Morgan Stanley | Equal-Weight | Initiate | |
| 2023-05-16 | Oppenheimer | Outperform | Initiate | |
| 2023-04-26 | Mizuho | Buy | Maintains | |
| 2023-04-26 | UBS | Neutral | Initiate | |
| 2023-04-19 | Piper Sandler | Overweight | Initiate | |
| 2023-04-18 | Mizuho | Buy | Maintains | |
| 2023-04-10 | BTIG | Neutral | Initiate | |
| 2023-03-13 | Evercore ISI Group | Outperform | Initiate | |
| 2023-02-17 | Mizuho | Buy | Initiate | |
| 2023-01-19 | Redburn Partners | Buy | Initiate | |
| 2023-01-04 | Edward Jones | Hold | Initiate | |
| 2025-07-31 | Citigroup | Buy | Buy | Maintains |
| 2025-07-31 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-09-09 | JP Morgan | Neutral | Initiate | |
| 2024-10-31 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-09-26 | UBS | Neutral | Sell | Downgrade |
| 2024-08-06 | Stifel | Buy | Initiate | |
| 2025-02-13 | Citigroup | Buy | Buy | Maintains |
| 2025-04-23 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-09-18 | BTIG | Neutral | Buy | Upgrade |
| 2025-01-08 | Jefferies | Hold | Buy | Upgrade |
| 2024-10-01 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-09-30 | Stifel | Buy | Buy | Maintains |
| 2025-02-14 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-03-11 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2025-07-09 | Citigroup | Buy | Buy | Maintains |
| 2025-05-06 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-05 | UBS | Sell | Neutral | Upgrade |
| 2025-05-01 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-05-01 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-05-01 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-04-30 | Citigroup | Buy | Buy | Maintains |
